Completion of US FDA inspection at Innoxel Lifesciences Pvt Ltd. Subsidiary company of Bharat Parentarals Limited.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals Limited's subsidiary Innoxel Lifesciences Pvt Ltd has successfully cleared a US FDA inspection at its manufacturing facility in Vadodara, Gujarat. The inspection ran from April 28 to May 2, 2025, and concluded with the issuance of a Form 483 containing only one minor observation, which the company describes as procedural in nature. Innoxel Lifesciences specialises in sterile injectable and complex dosage forms for regulated markets. The company will submit a detailed response to the FDA within the required timeframe. This result allows the subsidiary to continue serving the US market without disruption to its regulatory standing.
Positive for shareholders — clearing a US FDA audit with just one minor procedural observation is a strong outcome that preserves the subsidiary's eligibility to supply the lucrative US pharmaceutical market. This reinforces regulatory credibility and supports continued export-driven revenue from regulated markets.